2023-510365-10-00招募中1 期
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants with Type 1 Diabetes Mellitus.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 70
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Lilly Clinical Trials information desk
Scientific
Eli Lilly & Co.
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A study to investigate the safety and efficacy of TRK-750 for thetreatment of patients with CIPChemotherapy-induced peripheral neuropathyMedDRA version: 20.1Level: LLTClassification code 10079545Term: Chemotherapy induced peripheral neuropathySystem Organ Class: 100000004852EUCTR2019-003561-17-GBToray Industries, Inc.120
进行中（未招募）
1 期
A study to investigate the safety and efficacy of TRK-750 for thetreatment of patients with CIPChemotherapy-induced peripheral neuropathyMedDRA version: 20.1Level: LLTClassification code 10079545Term: Chemotherapy induced peripheral neuropathySystem Organ Class: 100000004852EUCTR2019-003561-17-ESToray Industries, Inc.120
进行中（未招募）
1 期
A study to investigate the safety and efficacy of TRK-750 for thetreatment of patients with CIPChemotherapy-induced peripheral neuropathyMedDRA version: 20.1Level: LLTClassification code 10079545Term: Chemotherapy induced peripheral neuropathySystem Organ Class: 100000004852EUCTR2019-003561-17-DEToray Industries, Inc.120
进行中（未招募）
1 期
A study to investigate the safety and efficacy of TRK-750 for thetreatment of patients with CIPEUCTR2019-003561-17-DKToray Industries, Inc.120
进行中（未招募）
1 期
A study to investigate the safety and efficacy of TRK-750 for the treatment of patients with CIPChemotherapy-induced peripheral neuropathyMedDRA version: 21.1Level: PTClassification code 10029331Term: Neuropathy peripheralSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-003561-17-ITToray Industries, Inc.120